Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
Status:
Terminated
Trial end date:
2018-01-29
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to test the effectiveness of Obeticholic Acid when used in
patients with moderately severe alcoholic hepatitis. The researchers suspect that individuals
with alcoholic hepatitis have certain abnormalities in how their body handles bile acids (a
product made by the liver on a daily basis) produced by the liver. Obeticholic acid has been
shown to affect bile acid abnormalities and thus it is possible that obeticholic acid may
improve liver condition in individuals with alcoholic hepatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Naga P. Chalasani
Collaborators:
Intercept Pharmaceuticals National Institute on Alcohol Abuse and Alcoholism (NIAAA)